| ［1］ |
Diaz MJ, Haq Z, Abdi P, et al. Association between alopecia areata and atopic dermatitis: a nested case⁃control study of the All of Us database［J］. J Am Acad Dermatol, 2023:S0190⁃9622（23）03034⁃03037. doi: 10.1016/j.jaad.2023.10.031.
|
| ［2］ |
Suárez⁃Fariñas M, Ungar B, Noda S, et al. Alopecia areata profiling shows TH1, TH2, and IL⁃23 cytokine activation without parallel TH17/TH22 skewing［J］. J Allergy Clin Immunol, 2015,136（5）:1277⁃1287. doi: 10.1016/j.jaci.2015.06.032.
|
| ［3］ |
Ito T, Kageyama R, Nakazawa S, et al. Understanding the significance of cytokines and chemokines in the pathogenesis of alopecia areata［J］. Exp Dermatol, 2020,29（8）:726⁃732. doi: 10.1111/exd.14129.
|
| ［4］ |
Zhang X, Zhao Y, Ye Y, et al. Lesional infiltration of mast cells, Langerhans cells, T cells and local cytokine profiles in alopecia areata［J］. Arch Dermatol Res, 2015,307（4）:319⁃331. doi: 10. 1007/s00403⁃015⁃1539⁃1.
|
| ［5］ |
Kridin K, Renert⁃Yuval Y, Guttman⁃Yassky E, et al. Alopecia areata is associated with atopic diathesis: results from a population⁃based study of 51,561 patients［J］. J Allergy Clin Immunol Pract, 2020,8（4）:1323⁃1328.e1. doi: 10.1016/j.jaip. 2020.01.052.
|
| ［6］ |
Solimani F, Meier K, Ghoreschi K. Emerging topical and systemic JAK inhibitors in dermatology［J］. Front Immunol, 2019,10:2847. doi: 10.3389/fimmu.2019.02847.
|
| ［7］ |
Phan K, Sebaratnam DF. JAK inhibitors for alopecia areata: a systematic review and meta⁃analysis［J］. J Eur Acad Dermatol Venereol, 2019,33（5）:850⁃856. doi: 10.1111/jdv.15489.
|
| ［8］ |
Vazquez ML, Kaila N, Strohbach JW, et al. Identification of N⁃{cis⁃3⁃［Methyl（7H⁃pyrrolo［2,3⁃d］pyrimidin⁃4⁃yl）amino］cyclobutyl}propane⁃1⁃sulfonamide （PF⁃04965842）: a selective JAK1 clinical candidate for the treatment of autoimmune diseases［J］. J Med Chem, 2018,61（3）:1130⁃1152. doi: 10.1021/acs.jmedchem.7b01598.
|
| ［9］ |
Asfour L, Getsos Colla T, Moussa A, et al. Concurrent chronic alopecia areata and severe atopic dermatitis successfully treated with upadacitinib［J］. Int J Dermatol, 2022,61（11）:e416⁃e417. doi: 10.1111/ijd.16316.
|
| ［10］ |
Cantelli M, Martora F, Patruno C, et al. Upadacitinib improved alopecia areata in a patient with atopic dermatitis: a case report［J］. Dermatol Ther, 2022,35（4）:e15346. doi: 10.1111/dth.15346.
|
| ［11］ |
Gambardella A, Licata G, Calabrese G, et al. Dual efficacy of upadacitinib in 2 patients with concomitant severe atopic dermatitis and alopecia areata［J］. Dermatitis, 2021,32（1S）:e85⁃e86. doi: 10.1097/DER.0000000000000780.
|
| ［12］ |
Gori N, Cappilli S, Di Stefani A, et al. Assessment of alopecia areata universalis successfully treated with upadacitinib［J］. Int J Dermatol, 2023,62（2）:e61⁃e63. doi: 10.1111/ijd.16342.
|
| ［13］ |
Novielli D, Foti C, Principi M, et al. Upadacitinib in concurrent Crohn′s disease, atopic dermatitis and alopecia areata: a case report［J/OL］. J Eur Acad Dermatol Venereol, 2023［2023⁃11⁃28］. doi: 10.1111/jdv.19377.
|
| ［14］ |
Kołcz K, Żychowska M, Sawińska E, et al. Alopecia universalis in an adolescent successfully treated with upadacitinib⁃a case report and review of the literature on the use of JAK inhibitors in pediatric alopecia areata［J］. Dermatol Ther （Heidelb）, 2023,13（3）:843⁃856. doi: 10.1007/s13555⁃023⁃00889⁃0.
|
| ［15］ |
Johnston LA, Poelman SM. Upadacitinib for management of recalcitrant alopecia areata: a retrospective case series［J］. JAAD Case Rep, 2023,35:38⁃42. doi: 10.1016/j.jdcr.2023.02. 019.
|
| ［16］ |
Walls B, Reguiai Z. Dual efficacy of upadacitinib in a patient with concomitant severe atopic dermatitis and alopecia areata［J］. Ann Dermatol Venereol, 2023:S0151⁃9638（23）00041⁃00048. doi: 10.1016/j.annder.2023.03.010.
|
| ［17］ |
Bourkas AN, Sibbald C. Upadacitinib for the treatment of alopecia areata and severe atopic dermatitis in a paediatric patient: a case report［J］. SAGE Open Med Case Rep, 2022,10:2050313X221138452. doi: 10.1177/2050313X221138452.
|
| ［18］ |
Johnston LA, Lu C, Poelman SM. Successful treatment of concomitant alopecia universalis and Crohn′s disease with upadacitinib: a case report［J］. SAGE Open Med Case Rep, 2023,11:2050313X231160914. doi: 10.1177/2050313X231160914.
|
| ［19］ |
Uchida H, Kamata M, Watanabe A, et al. Improvement of severe alopecia areata after 9⁃month baricitinib treatment followed by subsequent use of upadacitinib in a patient with atopic dermatitis［J］. J Dermatol, 2023,50（11）:e392⁃e393. doi: 10.1111/1346⁃8138.16893.
|
| ［20］ |
Youssef S, Bordone LA. Effective treatment of alopecia universalis with oral upadacitinib［J］. JAAD Case Rep, 2023,31:80⁃82. doi: 10.1016/j.jdcr.2022.08.014.
|
| ［21］ |
Chiricozzi A, Balato A, Fabbrocini G, et al. Beneficial effects of upadacitinib on alopecia areata associated with atopic dermatitis: a multicenter retrospective study［J］. J Am Acad Dermatol, 2023,89（6）:1251⁃1253. doi: 10.1016/j.jaad.2023.05.001.
|
